In addition, immunosuppressive CXCR2+ neutrophils have been recently associated with resistance to anti-PD-1 therapy in NASH-HCC patients, while CXCR2 antagonization resulted in restoration of the response to ICIs [113]. The gene discussed is CXCR2; the disease is hepatocellular carcinoma.